NCT04539548View on ClinicalTrials.gov

A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract

PHASE3CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

September 4, 2020

Primary Completion Date

December 21, 2023

Study Completion Date

December 21, 2023

Conditions
Cataract
Interventions
DRUG

Dextenza Ophthalmic Insert

0.4mg insert for intracanalicular use

DRUG

Prednisolone acetate ophthalmic suspension USP 1%

"1 drop at end of surgery, followed by:~1 drop 4 x QID for one week.~1 drop 3 x QID for one week.~1 drop BID for one week.~1 drop QD for one week"

Trial Locations (14)

16501

Ocular Therapeutix, Erie

23452

Ocular Therapeutix, Virginia Beach

29425

Ocular Therapeutix, Charleston

32202

Ocular Therapeutix, Jacksonville

37232

Ocular Therapeutix, Nashville

40508

Ocular Therapeutix, Lexington

46202

Ocular Therapeutix, Indianapolis

53705

Ocular Therapeutix, Madison

55454

Ocular Therapeutix, Minneapolis

55905

Ocular Therapeutix, Rochester

63110

Ocular Therapeutix, St Louis

80045

Ocular Therapeutix, Aurora

80525

Ocular Therapeutix, Fort Collins

02115

Ocular Therapeutix, Boston

Sponsors
All Listed Sponsors
lead

Ocular Therapeutix, Inc.

INDUSTRY

NCT04539548 - A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract | Biotech Hunter | Biotech Hunter